Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CRISPR Therapeutics AG

CRSP

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Last trade $40.56
Day change +$0.19 (+0.47%)
Day range $39.80 – $41.16
Volume 1,650,494
Market cap $3.92B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.92B
Price / earnings
—
Price / book
2.38×
Price / sales
155.57×
EV / sales
171.25×
EV / EBITDA
-8.39×

Profitability

Earnings per share
-$4.70
Return on assets
-17.84%
Return on equity
-27.68%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.36×
Current ratio
16.21×
Quick ratio
16.21×
Cash ratio
1.36×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$376.72M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRSP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$12.67M$10.18M$1.46M$864K$889K$892K$865K$35.69M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$12.67M$10.18M$1.46M$864K$889K$892K$865K$35.69M
Selling, general and administrative$17.87M$17.55M$17.18M$18.4M$16.93M$18.92M$19.3M$18.12M
Research and development$83.56M$69.63M$68.57M$83.53M$58.9M$166.15M$72.48M$71.74M
Total operating expenses$142.71M$127.45M$131.71M$155.63M$132.95M$230.22M$149.29M$100.28M
Operating income-$130.05M-$117.27M-$130.25M-$154.76M-$132.06M-$229.32M-$148.42M-$64.59M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$111.36M-$90.19M-$122.09M-$130M-$105.82M-$207.26M-$134.89M-$36.61M
Income taxes$74K$960K$839K$614K$619K$1.29M$1.11M$700K
Net income-$111.44M-$91.15M-$122.93M-$130.61M-$106.44M-$208.55M-$136M-$37.31M
Net income attributable to common shareholders-$111.44M-$91.15M-$122.93M-$130.61M-$106.44M-$208.55M-$136M-$37.31M
EBITDA-$125.81M-$112.99M-$125.93M-$149.1M-$127.63M-$224.68M-$143.69M-$59.75M
Basic earnings per share-$1.15-$0.94-$1.28-$1.37-$1.17-$2.40-$1.58-$0.44
Diluted earnings per share-$1.15-$0.94-$1.28-$1.37-$1.17-$2.40-$1.58-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics (CRSP) has been among the most searched stocks on Zacks.com. The stock has declined 19.3% over the past month, underperforming the S&P 500's -3% decline. While the company shows strong revenue growth projections (+873.2% for current fiscal year and +237.7% for next year), it carries a Zacks Rank #3 (Hold) rating and is trading at a premium valuation (F grade) relative to peers. The company is expected to remain unprofitable in the near term.

The Motley Fool

Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

The article compares Amgen and Vertex Pharmaceuticals as investment options for 2027. Amgen offers diversified revenue streams across multiple drug franchises with lower valuation metrics but faces biosimilar competition and pricing pressures. Vertex demonstrates faster growth driven by cystic fibrosis dominance and promising pipeline candidates like Povetacicept, though at a premium valuation. The analyst recommends Vertex for long-term growth investors despite higher valuations, citing its superior growth trajectory and innovative pipeline.

GlobeNewswire Inc.

CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases

CRISPR Therapeutics reported encouraging Phase 1 clinical data for zugo-cel, its allogeneic CAR-T cell therapy, across multiple autoimmune disease indications. In systemic sclerosis, 83% of patients achieved clinical response at Month 3 with maintained responses through Month 6+. All nine idiopathic inflammatory myopathy patients showed moderate to major improvement. The therapy demonstrated a favorable safety profile with no serious adverse events reported across 21 dosed patients. Dose escalation studies are ongoing with higher CAR-T cell expansion observed at increased dose levels.

The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics (CRSP) is receiving increased investor attention. The stock has underperformed the S&P 500 over the past month (-3.7% vs -5.4%). While the company shows strong revenue growth projections (+771.8% for current fiscal year), it carries a Zacks Rank #3 (Hold) rating and trades at a premium valuation (F grade). The company is expected to turn profitable next fiscal year with projected EPS of $3.73.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.